Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Gallstones Male or female age 18 to 75 years. 2. Presence of newly formed gallstones (size up to 6 mm) with or without sludge diagnosed by ultrasound within 3 or 6 months after bariatric surgery following normal ultrasound. 3. Bariatric surgery conducted during the last 12 months 4. Patients with "sleeve gastrectomy" or laparoscopic banding of the upper stomach will be included. 5. Signature of the written informed consent. 6. Negative pregnancy test at study entry for females of child bearing potential. 7. Females of child bearing potential practicing reliable contraception throughout the study period (not including oral contraceptives). 8. Hypertensive patients must be well controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening (and the stable dose can be maintained throughout the study). 9. Patients treated with vitamin E(>400IU/die), or Polyunsaturated fatty acid (>2g/d) or Ursodeoxycholic acid or fish oil can be included if drugs are stopped at least 3 months prior to study enrollment to the study and up to it end. 10. For patients with type 2 Diabetes, glycaemia must be controlled (Glycosylated Hemoglobin A1C ≤ 8% while any HbA1C increment should not exceed 1% during 6 month prior to enrollment). If glycaemia is controlled by medications, qualitative change is not permitted within 3 months prior to randomization and should be avoided during the study. Treatments with Metformin, Sulfamides and Insulin are authorized. Sulfamides and insulin are permitted if glycaemia is self-monitored by the patient  Patients with ultrasonography evidence of gallstones in gallbladder before having the bariatric surgery. 2. Patients with no clear ultrasonography evidence of gallstones -free gallbladder during the year prior their bariatric surgery. 3. Patients with ultrasonography evidence of gallstones more than 1 year following bariatric surgery. 4. Patients with ultrasonography evidence of gallstones in size greater than 9 mm less than 1 year following bariatric surgery. 5. Weight >140 Kg or BMI >40 6. Known alcohol and/or any other drug abuse or dependence in the last five years 7. Known history or presence of clinically significant cardiovascular, hepatic, gastrointestinal, neurologic, pulmonary, endocrine, psychiatric, neoplastic disorder or nephritic syndrome. 8. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including bile salt metabolism (e.g. inflammatory bowel disease (IDB); previous intestinal (ileal or colonic) operation; chronic pancreatic; celiac disease or previous vagotomy 9. Uncontrolled blood pressure 10. Patients with HIV 11. Patients with renal dysfunction eGFR< 60. 12. Patients with pancreatitis, cholangitis or cholecystitis in the previous 4 months. 13. Women who are pregnant or breastfeeding 14. Type 1 Diabetes. 15. .Metformin, Fibrates, Statins, Insulin, Sulfonilurea not provided on a stable dose in the last 6 months. 16. Patients who are treated with Valproic acid, Tamoxifen, Methotreksate, Amiodaron. 17. Treatment with Rifaximin. 18. Homeopathic and/or Alternative treatments. Any treatment should be stopped before the screening period. 19. Serum creatine phosphokinase (CPK), ALT, AST and/or alkaline phosphatase >3X the upper limit of normal (ULN). Patients with an intermittent CPK elevation may have the repeated measurement prior to randomization; a CPK retest > 3X ULN leads to exclusion. -